MedTrace Logo

Immune Modulation by Ischemic Pre-conditioning in Healthy Individuals: Intracellular Signalling in Regulatory Cells

NCT03541239 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-03-22

No results posted yet for this study

Summary

The aim of the study is to investigate how phosphorylation of STAT3, p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK) and protein kinase B (AKT) reacts to remote ischemic conditioning (rIC) in healthy humans, which could point to mechanisms by which rIC may protect against ischemia-reperfusion injury (IRI), and if rIC affects immune reactivity.

Conditions

  • Ischemia Reperfusion Injury
  • Ischaemia Reperfusion Injury

Interventions

DEVICE

Single Cuff Tourniquet 8000

If randomized to ischemic conditioning the cuff will be inflated as stated before. If randomized to non-ischemic conditioning the cuff will not be inflated.

Sponsors & Collaborators

  • Fonden til Lægevidenskabens Fremme

    collaborator OTHER

  • Erasmus Medical Center

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Bente Jespersen, Professor · Dept. of Renal Diseases, SKS, DK

  • Bjarne Kuno Møller, MD · Dept. of Clinical Immunology, SKS, DK

  • Carla Baan, Professor · Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-07-19
Completion
2016-07-19

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03541239 on ClinicalTrials.gov